This HTML5 document contains 87 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n18http://www.rxlist.com/cgi/generic3/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n17http://linked.opendata.cz/resource/AHFS/
foafhttp://xmlns.com/foaf/0.1/
n12http://linked.opendata.cz/resource/mesh/concept/
n26http://linked.opendata.cz/resource/drugbank/drug/DB00319/identifier/kegg-drug/
n6http://linked.opendata.cz/resource/drugbank/company/
n21http://linked.opendata.cz/resource/drugbank/drug/DB00319/identifier/drugbank/
n13http://linked.opendata.cz/resource/drugbank/mixture/
n23http://linked.opendata.cz/resource/drugbank/drug/DB00319/identifier/national-drug-code-directory/
n8http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n22http://linked.opendata.cz/resource/drugbank/drug/DB00319/identifier/chebi/
n14http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n4http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n11http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n27http://linked.opendata.cz/resource/drugbank/drug/DB00319/identifier/wikipedia/
n10http://www.drugs.com/cdi/
n5http://linked.opendata.cz/resource/drugbank/property/
n24http://linked.opendata.cz/resource/drugbank/drug/DB00319/identifier/pharmgkb/
xsdhhttp://www.w3.org/2001/XMLSchema#
n25http://linked.opendata.cz/resource/drugbank/drug/DB00319/identifier/kegg-compound/
n19http://linked.opendata.cz/resource/atc/
n16http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00319
rdf:type
n3:Drug
n3:description
Semisynthetic, broad-spectrum, ampicillin derived ureidopenicillin antibiotic proposed for pseudomonas infections. It is also used in combination with other antibiotics. [PubChem]
n3:generalReferences
# Lau WK, Mercer D, Itani KM, Nicolau DP, Kuti JL, Mansfield D, Dana A: Randomized, open-label, comparative study of piperacillin-tazobactam administered by continuous infusion versus intermittent infusion for treatment of hospitalized patients with complicated intra-abdominal infection. Antimicrob Agents Chemother. 2006 Nov;50(11):3556-61. Epub 2006 Aug 28. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16940077
n3:group
approved
n3:halfLife
36-72 minutes
n3:indication
For the treatment of polymicrobial infections.
n3:manufacturer
n6:271B535A-363D-11E5-9242-09173F13E4C5 n6:271B5359-363D-11E5-9242-09173F13E4C5
owl:sameAs
n8:DB00319 n14:DB00319
dcterms:title
Piperacillin
adms:identifier
n21:DB00319 n22:8232 n23:0206-3879-16 n24:PA450975 n25:C07361 n26:D00466 n27:Piperacillin
n3:mechanismOfAction
By binding to specific penicillin-binding proteins (PBPs) located inside the bacterial cell wall, Piperacillin inhibits the third and last stage of bacterial cell wall synthesis. Cell lysis is then mediated by bacterial cell wall autolytic enzymes such as autolysins; it is possible that Piperacillin interferes with an autolysin inhibitor.
n3:packager
n6:271B5358-363D-11E5-9242-09173F13E4C5 n6:271B5357-363D-11E5-9242-09173F13E4C5
n3:routeOfElimination
As with other penicillins, PIPRACIL is eliminated primarily by glomerular filtration and tubular secretion; it is excreted rapidly as unchanged drug in high concentrations in the urine. Because PIPRACIL is excreted by the biliary route as well as by the renal route, it can be used safely in appropriate dosage in patients with severely restricted kidney function.
n3:synonym
Piperacilina (2S,5R,6R)-6-{[(2R)-2-{[(4-ethyl-2,3-dioxopiperazin-1-yl)carbonyl]amino}-2-phenylacetyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Piperacillina Piperacillin Piperacillin Anhydrous Piperacillinum Pipéracilline
n3:volumeOfDistribution
* 101 mL/kg [intravenous administration of 50 mg/kg (5-minute infusion) in neonates]
n16:hasAHFSCode
n17:08-12-16-16
n3:mixture
n13:271B5355-363D-11E5-9242-09173F13E4C5 n13:271B5356-363D-11E5-9242-09173F13E4C5 n13:271B534B-363D-11E5-9242-09173F13E4C5 n13:271B534C-363D-11E5-9242-09173F13E4C5 n13:271B5349-363D-11E5-9242-09173F13E4C5 n13:271B534A-363D-11E5-9242-09173F13E4C5 n13:271B534F-363D-11E5-9242-09173F13E4C5 n13:271B5350-363D-11E5-9242-09173F13E4C5 n13:271B534D-363D-11E5-9242-09173F13E4C5 n13:271B534E-363D-11E5-9242-09173F13E4C5 n13:271B5353-363D-11E5-9242-09173F13E4C5 n13:271B5354-363D-11E5-9242-09173F13E4C5 n13:271B5351-363D-11E5-9242-09173F13E4C5 n13:271B5352-363D-11E5-9242-09173F13E4C5
n3:salt
n3:synthesisReference
Bruce E. Haeger, "Composition of matter comprising a low bulk density lyophilized preparation of Sodium Piperacillin." U.S. Patent US4534977, issued October, 1984.
n11:hasConcept
n12:M0016883
foaf:page
n10:piperacillin.html n18:piperacillin.htm
n3:IUPAC-Name
n5:271B5363-363D-11E5-9242-09173F13E4C5
n3:InChI
n5:271B5369-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n5:271B5368-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n5:271B5365-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n5:271B5366-363D-11E5-9242-09173F13E4C5
n3:SMILES
n5:271B5367-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n5:271B5361-363D-11E5-9242-09173F13E4C5
n3:logP
n5:271B535F-363D-11E5-9242-09173F13E4C5 n5:271B5362-363D-11E5-9242-09173F13E4C5 n5:271B5379-363D-11E5-9242-09173F13E4C5
n3:logS
n5:271B5360-363D-11E5-9242-09173F13E4C5
n16:hasATCCode
n19:J01CA12
n3:H-Bond-Acceptor-Count
n5:271B536F-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n5:271B5370-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n5:271B536A-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n5:271B536B-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n5:271B536D-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n5:271B536C-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n5:271B536E-363D-11E5-9242-09173F13E4C5
n3:absorption
Not absorbed following oral administration.
n3:affectedOrganism
Enteric bacteria and other eubacteria
n3:casRegistryNumber
66258-76-2
n3:category
n3:clearance
* 32 - 41 mL/min/1.73 m2 * 124 - 160 mL/min/1.73 m2 [older pediatric patients]
n3:containedIn
n4:271B535E-363D-11E5-9242-09173F13E4C5 n4:271B535C-363D-11E5-9242-09173F13E4C5 n4:271B535D-363D-11E5-9242-09173F13E4C5 n4:271B535B-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n5:271B5375-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n5:271B5377-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n5:271B5378-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n5:271B5374-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n5:271B5373-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n5:271B5376-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n5:271B5364-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n5:271B5371-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n5:271B5372-363D-11E5-9242-09173F13E4C5